Akebia Therapeutics, Inc. (AKBA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.97-0.87%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AKBA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | 219.1 | 236.2 | 160.2 | 194.6 | 292.5 | 211.7 | 294.6 | 335.0 | 207.7 | — | — | 0.0 | 0.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 |
| Cost of Revenues | 44.6 | 39.5 | 63.2 | 74.1 | 85.6 | 150.7 | 296.5 | 108.9 | 6.3 | — | — | — | — |
| Operating Expenses & Income | |||||||||||||
| Selling, General & Admin | 113.8 | 107.5 | 106.5 | 100.2 | 138.6 | 174.1 | 154.1 | 149.5 | 87.1 | — | — | — | — |
| R&D Expenses | 70.5 | 62.4 | 37.7 | 63.1 | 130.0 | 147.9 | 218.5 | 323.0 | 291.0 | 230.9 | 115.8 | 43.0 | 23.3 |
| Operating Income | (15.1) | 23.5 | (50.5) | (46.3) | (80.8) | (264.5) | (377.8) | (286.3) | (178.2) | (76.7) | (136.5) | (61.5) | (37.9) |
| Earnings from Continuing Operations | |||||||||||||
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | 0.9 | — | — |
| EBT, Incl. Unusual Items | (27.8) | (3.7) | (69.4) | (51.9) | (94.2) | (282.0) | (384.8) | (286.3) | (171.9) | — | — | — | — |
| Income Tax Expense | 1.8 | 1.6 | — | 0.0 | 0.0 | 0.0 | 0.0 | (6.6) | (28.3) | — | — | — | — |
| Net Income | |||||||||||||
| Net Income | (29.6) | (5.3) | (69.4) | (51.9) | (94.2) | (282.0) | (384.8) | (279.7) | (143.6) | (73.7) | (135.7) | (60.7) | (37.0) |
| Per Share | |||||||||||||
| Basic EPS | (0.11) | (0.02) | (0.33) | (0.28) | (0.52) | (1.70) | (2.78) | — | — | — | — | — | — |
| Diluted EPS | (0.11) | (0.02) | (0.33) | (0.28) | (0.52) | (1.70) | (2.78) | — | — | — | — | — | — |
| Revenue per Share | 0.81 | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 269.6 | 257.2 | 210.9 | 187.5 | 182.8 | 165.9 | 138.5 | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 269.6 | 257.2 | 210.9 | 187.5 | 182.8 | 165.9 | 138.5 | — | — | — | — | — | — |
| Supplemental | |||||||||||||
| EBITDA | — | — | — | — | (79.1) | (262.6) | (375.8) | (284.0) | (177.3) | (76.1) | (136.2) | — | — |
| EBIT | (15.1) | 23.5 | (50.5) | (46.3) | (80.8) | (264.5) | (377.8) | (286.3) | (178.2) | (76.7) | (136.5) | (61.5) | (37.9) |
| Effective Tax Rate | -6.5% | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 2.3% | 16.5% | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.